← Leaderboards
Andrew D Goodman
University Of Rochester
$8,460,689
Attributed
$8,460,689
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
CDC$8,391,881 · 1
NIH$68,808 · 2
By mechanism
U58$8,391,881 · 1
M01$68,808 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Ignacio E. Sanz$71,521,451
- Jacques Robert$11,910,879
- Arthur J. Moss$13,356,209
- Francis Gigliotti$9,264,116
- Sabine M Brouxhon$3,578,999
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchMultiple SclerosisPharmacokineticsDrug Screening /EvaluationNervous System Disorder ChemotherapyAcute Disease /DisorderCell Adhesion MoleculesClinical TrialsMonoclonal AntibodyRelapse /RecurrenceOral AdministrationDosagePyridineSlow Release DrugElectrocardiography
Grant awards (6)
Public Prevention Health Fund: Community Transformation Grants$8,391,881
U58 · FY2011 · DP · contact PI
STUDY OF IV ANTEGREN IN PATIENTS WITH MS DURING ACUTE EXASERBATION$0
M01 · FY2002 · RR
STUDY OF IV ANTEGREN IN PATIENTS WITH MS DURING ACUTE EXASERBATION$19,613
M01 · FY2001 · RR
STUDY TO ASSESS PHARMACOKINETICS OF ESC DOSE OF FAMPRIDINEIN IN MS PATIENTS$19,613
M01 · FY2001 · RR
STUDY OF IV ANTEGREN IN PATIENTS WITH MS DURING ACUTE EXASERBATION$14,791
M01 · FY2000 · RR
STUDY TO ASSESS PHARMACOKINETICS OF ESC DOSE OF FAMPRIDINEIN IN MS PATIENTS$14,791
M01 · FY2000 · RR